NeoGenomics Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

NeoGenomics Stock Summary

NeoGenomics competes with Molecular Partners, MediciNova, Anebulo Pharmaceuticals, Shattuck Labs, and Eliem Therapeutics. NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. The company was founded in 2001 and is headquartered in Fort Myers, Florida. Neogenomics operates under Diagnostics Research classification in the United States and is traded on NASDAQ Exchange. It employs 2000 people.

NeoGenomics Key Financial Ratios

NeoGenomics Key Balance Sheet Accounts

NeoGenomics Key Income Statement Accounts

NeoGenomics Key Cash Accounts

NeoGenomics Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining NeoGenomics's current stock value. Our valuation model uses many indicators to compare NeoGenomics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NeoGenomics competition to find correlations between indicators driving NeoGenomics's intrinsic value. More Info.NeoGenomics is considered to be number one stock in return on equity category among its peers. It also is considered to be number one stock in return on asset category among its peers . At this time, NeoGenomics' Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the NeoGenomics' earnings, one of the primary drivers of an investment's value.

NeoGenomics Systematic Risk

Today, most investors in NeoGenomics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various NeoGenomics' growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of NeoGenomics growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of NeoGenomics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of NeoGenomics. We use our internally-developed statistical techniques to arrive at the intrinsic value of NeoGenomics based on widely used predictive technical indicators. In general, we focus on analyzing NeoGenomics Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build NeoGenomics's daily price indicators and compare them against related drivers.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NeoGenomics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in NeoGenomics Stock, please use our How to Invest in NeoGenomics guide.You can also try the Equity Search module to search for actively traded equities including funds and ETFs from over 30 global markets.

Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeoGenomics. If investors know NeoGenomics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeoGenomics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of NeoGenomics is measured differently than its book value, which is the value of NeoGenomics that is recorded on the company's balance sheet. Investors also form their own opinion of NeoGenomics' value that differs from its market value or its book value, called intrinsic value, which is NeoGenomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeoGenomics' market value can be influenced by many factors that don't directly affect NeoGenomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between NeoGenomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeoGenomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeoGenomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.